Hormone-Replacement Therapy and Its Association with Breast Cancer Subtypes: A Large Retrospective Cohort Study

References

• Fitzmaurice C, Abate D, Abbasi N, et al.. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5:1749–1768.
   PubMed Web of Science ®Google Scholar
• Health at a glance 2017: OECD indicators. Available from: http://www.oecd.org/health/health-systems/health-at-a-glance-19991312.htm. Accessed November 19, 2021.
   Google Scholar
• Iwamoto Y, Kaucher S, Lorenz E, Barnighausen T, Winkler V. Development of breast cancer mortality considering the implementation of mammography screening programs - a comparison of Western European countries. BMC Public Health. 2019;19(1):823. doi:10.1186/s12889-019-7166-6
   Web of Science ®Google Scholar
• Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends–an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27. doi:10.1158/1055-9965.EPI-15-0578
   PubMed Web of Science ®Google Scholar
• Siu AL; Force USPST. Screening for breast cancer: U.S. preventive services task force recommendation statement. Ann Intern Med. 2016;164(4):279–296. doi:10.7326/M15-2886
   PubMed Web of Science ®Google Scholar
• U.S. preventive services task force: final recommendation statement. Breast cancer: screening. Available from: https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/breast-cancer-screening1. Accessed November 19, 2021.
   Google Scholar
• Breast cancer in women in Israel - a report on prevalence and mortality in 2018. Available from: https://www.health.gov.il/PublicationsFiles/breast_cancer_SEPT2018.pdf. Accessed November 19, 2021.
   Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA. 2002;288(3):321–333. doi:10.1001/jama.288.3.321
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010;304(15):1684–1692. doi:10.1001/jama.2010.1500
   PubMed Web of Science ®Google Scholar
• Verkooijen HM, Bouchardy C, Vinh-Hung V, Rapiti E, Hartman M. The incidence of breast cancer and changes in the use of hormone replacement therapy: a review of the evidence. Maturitas. 2009;64(2):80–85. doi:10.1016/j.maturitas.2009.07.015
   Web of Science ®Google Scholar
• Silverman BG, Siegelmann-Danieli N, Braunstein R, Kokia ES. Trends in breast cancer incidence associated with reductions in the use of hormone replacement therapy. Cancer Epidemiol. 2011;35(1):11–16. doi:10.1016/j.canep.2010.11.006
   Web of Science ®Google Scholar
• Siegelmann-Danieli N, Katzir I, Landes JV, et al. Does levonorgestrel-releasing intrauterine system increase breast cancer risk in peri-menopausal women? An HMO perspective. Breast Cancer Res Treat. 2018;167(1):257–262. doi:10.1007/s10549-017-4491-2
   Web of Science ®Google Scholar
• Giordano SH, Temin S, Chandarlapaty S, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2–positive breast cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(26):2736–2740. doi:10.1200/JCO.2018.79.2697
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Cancer Stat Facts: Female Breast Cancer Subtypes 2014-2018. Available from: https://seer.cancer.gov/statfacts/html/breast-subtypes.html. Accessed: 22 Jul 2021
   Google Scholar
• Seradour B, Allemand H, Weill A, Ricordeau P. Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006. Bull Cancer. 2009;96(4):E1–E6. doi:10.1684/bdc.2009.0869
   Google Scholar
• Robbins AS, Clarke CA. Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol. 2007;25(23):3437–3439. doi:10.1200/JCO.2007.11.4132
   Web of Science ®Google Scholar
• Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007;356(16):1670–1674. doi:10.1056/NEJMsr070105
   PubMed Web of Science ®Google Scholar
• Parkin DM. Is the recent fall in incidence of post-menopausal breast cancer in UK related to changes in use of hormone replacement therapy? Eur J Cancer. 2009;45(9):1649–1653. doi:10.1016/j.ejca.2009.01.016
   PubMed Web of Science ®Google Scholar
• Marshall SF, Clarke CA, Deapen D, et al. Recent breast cancer incidence trends according to hormone therapy use: the California Teachers Study cohort. Breast Cancer Res. 2010;12(1):R4. doi:10.1186/bcr2467
   Web of Science ®Google Scholar
• Kerlikowske K, Miglioretti DL, Buist DS, Walker R, Carney PA. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 2007;99(17):1335–1339. doi:10.1093/jnci/djm111
   Google Scholar
• Glass AG, Lacey JV, Carreon JD, Hoover RN. Breast cancer incidence, 1980–2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst. 2007;99(15):1152–1161. doi:10.1093/jnci/djm059
   Google Scholar
• Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol. 2006;24(33):e49–50. doi:10.1200/JCO.2006.08.6504
   PubMedGoogle Scholar
• Canfell K, Banks E, Moa AM, Beral V. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust. 2008;188(11):641–644. doi:10.5694/j.1326-5377.2008.tb01821.x
   PubMed Web of Science ®Google Scholar
• De P, Neutel CI, Olivotto I, Morrison H. Breast cancer incidence and hormone replacement therapy in Canada. J Natl Cancer Inst. 2010;102(19):1489–1495. doi:10.1093/jnci/djq345
   PubMedGoogle Scholar
• Breast cancer in women in Israel. Available from: https://www.health.gov.il/PublicationsFiles/breast_cancer_sept2020.pdf. Accessed November 19, 2021.
   Google Scholar
• Salagame U, Banks E, O’Connell DL, Egger S, Canfell K. Menopausal hormone therapy use and breast cancer risk by receptor subtypes: results from the New South Wales Cancer Lifestyle and EvaluAtion of Risk (CLEAR) study. PLoS One. 2018;13(11):e0205034. doi:10.1371/journal.pone.0205034
   PubMed Web of Science ®Google Scholar
• Ellingjord-Dale M, Vos L, Tretli S, Hofvind S, Dos-Santos-Silva I, Ursin G. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program. Breast Cancer Res. 2017;19(1):10. doi:10.1186/s13058-016-0798-x
   PubMed Web of Science ®Google Scholar
• Kumle M. Declining breast cancer incidence and decreased HRT use. Lancet. 2008;372(9639):608–610. doi:10.1016/S0140-6736(08)61255-6
   Web of Science ®Google Scholar
• Canfell K, Banks E, Clements M, et al. Sustained lower rates of HRT prescribing and breast cancer incidence in Australia since 2003. Breast Cancer Res Treat. 2009;117(3):671–673. doi:10.1007/s10549-009-0331-3
   PubMed Web of Science ®Google Scholar
• Saxena T, Lee E, Henderson KD, et al. Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study. Cancer Epidemiol Biomarkers Prev. 2010;19(9):2366–2378. doi:10.1158/1055-9965.EPI-10-0162
   Web of Science ®Google Scholar
• Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer. 2004;101(7):1490–1500. doi:10.1002/cncr.20499
   Web of Science ®Google Scholar
• Beral V, Reeves G, Bull D, Green J; Million Women Study C. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst. 2011;103(4):296–305. doi:10.1093/jnci/djq527
   PubMedGoogle Scholar
• Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC, Henderson BE. Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study. Am J Epidemiol. 2009;169(10):1251–1259. doi:10.1093/aje/kwp036
   Web of Science ®Google Scholar
• Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ. 2020;371:m3873. doi:10.1136/bmj.m3873
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast C. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159–1168. doi:10.1016/S0140-6736(19)31709-X
   Web of Science ®Google Scholar
• Dietel M, Lewis MA, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod. 2005;20(8):2052–2060. doi:10.1093/humrep/dei043
   PubMed Web of Science ®Google Scholar
• Beral V, Peto R, Pirie K, Reeves G. Menopausal hormone therapy and 20-year breast cancer mortality. Lancet. 2019;394(10204):1139. doi:10.1016/S0140-6736(19)32033-1
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Anderson GL, Aragaki AK, et al.: Long-term influence of estrogen plus progestin and estrogen alone use on breast cancer incidence: the Women’s Health Initiative randomized trials. Abstract GS5-00. San Antonio, TX: San Antonio Breast Cancer Symposium (SABCS); 2019.
   Google Scholar